TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05197972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac coherence program coupled with hypnosis
Description: At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape).
Study: NCT04735471

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADI-001
Description: Anti-CD20 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for Lymphodepletion
Study: NCT06326060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide will be administered subcutaneously.
Study: NCT05472779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periurethral application of estradiol cream
Description: The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal application of estradiol cream
Description: The control group will apply 1 gram estradiol cream intravaginally using an applicator.
Study: NCT04599010

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: energy-restricted diet appropriate for resting metabolic rate using FFM as proxy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
Study: NCT05902117

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Troponin and Copeptin assay
Description: Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
Study: NCT04971642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral ultrasound
Description: Intraoral ultrasound scanning of the periodontium complex
Study: NCT05655299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose A
Description: Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose B
Description: Dose B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose C
Description: Dose C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958 Dose D
Description: Dose D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04908631

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Stimulation
Description: Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.

Intervention type: OTHER
Group type: OTHER
Intervention: Auditory Training Program
Description: Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
Study: NCT05754645

Intervention type: OTHER
Intervention: Blood withdrawal
Description: venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
Study: NCT05867368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-VR
Description: HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HABIT
Description: HABIT is a camp where children play self-select activities that require both hands to succeed.
Study: NCT06651541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A
Description: Formulation with the active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation without the active ingredient
Study: NCT05703607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 1: PF-07915234: VZV modRNA Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 3: PF-07921186: VZV modRNA Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Selected Vaccine Candidate group (Dose level, Schedule)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix - SSB
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Description: Intramuscular injection
Study: NCT06462794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-801
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-801
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Standard of Care Therapy
Study: NCT05897658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT06287580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorthalidone 25 mg
Description: chlorthalidone, 25 mg orally once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once daily
Study: NCT04856046

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT06138054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBTech
Description: Three in-person MI sessions focused on identifying goals for community integration (in the areas of vocational, recreational, social, or independent living activities) and unhelpful thinking that tends to get in the way of those goals, building motivation for goals, introducing participants to the CBT model and its potential benefits, and downloading and orienting them to the mobile phone application.~Six weeks of mobile phone application use to guide participants through CBT. Weekly content will be provided to learn and practice CBT skills to address unhelpful thinking and problem solving to address obstacles to goal attainment. There will be brief content pages worksheets to guide participants through practice. The worksheets will be tailored to each participant, framing the skills around their pre-identified goals and unhelpful thinking patterns. The application will also include access to crisis resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness control
Description: Three in-person supportive therapy sessions focused on empathic listening during client-led discussions of presenting concerns, introducing participants to mindfulness (defined as noticing and paying attention to the present moment without judgment), and downloading and orienting them to the mobile phone application. Participants will be informed of potential benefits of mindfulness, including stress reduction and increased self-awareness.~Six weeks of mindfulness training mobile application use to help participants learn to practice mindfulness through a gradual, self-guided training program. The application offers a library of information about mindfulness, 12 different audio-guided mindfulness exercises, goal-setting and tracking, customizable reminders, and access to crisis resources.
Study: NCT05384405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active iTBS
Description: MagPro X100

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: MagPro X100
Study: NCT05946057

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular genetic testing and audiometry
Description: Genetic testing and audiometry are the interventions of interest
Study: NCT05813639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch cryo ablation neurotomy
Description: The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch radiofrequency ablation neurotomy
Description: The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic denervation of fazet joint
Description: The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
Study: NCT04722939

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral oxygenation
Description: Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
Study: NCT06043583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine device
Description: The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery embolization
Description: The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
Study: NCT05902364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400 and propylene glycol solution/drops
Description: commercially available eye drops
Study: NCT04791579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Fluoroquinolone antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT04867616

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive Placebo during the Double-blind Treatment Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bepranemab
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bepranemab
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bepranemab
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: Intravenous infusion~Participants will receive pre-specified doses of bepranemab during the Double-blind Treatment Period and the Open-label Extension Period.
Study: NCT06193096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Probiotic mix (i3.1) comprising Pediococcus acidilactici KABPTM 021, Lactiplantibacillus plantarum KABPTM 022 and Lactiplantibacillus plantarum KABPTM 023 in a 1:1:1 ratio and with a total concentration of ≥3x10\^9 total colony forming units (CFU) per sachet (stick). Other ingredients are dextrose and maltodextrin as excipients, aroma, flavorings and silicon dioxide. Experimental product will be taken over 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Placebo product containing dextrose and maltodextrin, aroma, flavorings and silicon dioxide.~Control product will be taken over to weeks
Study: NCT06284343

Intervention type: DRUG
Intervention: Anticoagulant
Description: Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
Study: NCT05773755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept PC DBS system
Description: Open label active Deep Brain Stimulation (DBS)
Study: NCT05431933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eupolio
Description: Inactivated Polio vaccine (Sabin strains)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eupolio
Description: Inactivated Polio vaccine (Sabin strains)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eupolio
Description: Inactivated Polio vaccine (Sabin strains)
Study: NCT05030129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Description: 5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Description: 5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoloid Mesylates
Description: Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoloid Mesylates
Description: Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for Ergoloid mesylates
Description: Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for Ergoloid mesylates
Description: Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for 5-Hydroxytryptophan
Description: Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for 5-Hydroxytryptophan
Description: Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
Study: NCT06651606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Ratio Training (PRT)
Description: Progressive ratio training (PRT) is used to prevent recurrence of the proxy response when extinction errors occur. PRT involves providing a reinforcer for the proxy response on a geometric progressive ratio (PR) scale. The schedule requirement will increase for the target response each time a reinforcer is delivered. For example, once a reinforcer is delivered on the PR-2 schedule, the requirement will increase to a PR-4, then to a PR-8, -16,~-32, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differential Reinforcement of Alternative (DRA) Behavior with Extinction
Description: In DRA with extinction, the proxy for problem behavior is placed on extinction and no longer produces reinforcement. The proxy for communication behavior produces reinforcement on a fixed-ratio 1 schedule of reinforcement.
Study: NCT06651853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
Description: Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent.